Torsdag 12 Mars | 00:20:31 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2027-02-16 08:30 Bokslutskommuniké 2026
2026-11-03 08:30 Kvartalsrapport 2026-Q3
2026-09-01 08:30 Kvartalsrapport 2026-Q2
2026-05-29 N/A X-dag ordinarie utdelning IZAFE B 0.00 SEK
2026-05-28 N/A Årsstämma
2026-04-28 08:30 Kvartalsrapport 2026-Q1
2026-03-12 N/A Extra Bolagsstämma 2026
2026-02-16 - Bokslutskommuniké 2025
2025-11-03 - Kvartalsrapport 2025-Q3
2025-08-29 - Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2025-05-28 - Årsstämma
2025-04-25 - Kvartalsrapport 2025-Q1
2025-02-14 - Bokslutskommuniké 2024
2024-11-01 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-31 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2024-05-30 - Årsstämma
2024-04-26 - Kvartalsrapport 2024-Q1
2024-02-09 - Bokslutskommuniké 2023
2023-12-21 - Extra Bolagsstämma 2024
2023-11-17 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-12 - Kvartalsrapport 2023-Q1
2023-04-06 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2023-04-05 - Årsstämma
2023-02-03 - Bokslutskommuniké 2022
2022-11-07 - Kvartalsrapport 2022-Q3
2022-10-05 - Extra Bolagsstämma 2022
2022-08-26 - Kvartalsrapport 2022-Q2
2022-06-15 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2022-06-14 - Årsstämma
2022-04-29 - Kvartalsrapport 2022-Q1
2022-02-18 - Bokslutskommuniké 2021
2021-11-29 - Kvartalsrapport 2021-Q3
2021-09-23 - Extra Bolagsstämma 2021
2021-08-30 - Kvartalsrapport 2021-Q2
2021-06-28 - Årsstämma
2021-06-15 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2021-04-29 - Kvartalsrapport 2021-Q1
2021-02-19 - Bokslutskommuniké 2020
2020-11-09 - Kvartalsrapport 2020-Q3
2020-08-17 - Kvartalsrapport 2020-Q2
2020-06-26 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2020-06-25 - Årsstämma
2020-05-11 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-05-10 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2019-05-06 - Kvartalsrapport 2019-Q1
2019-04-10 - Årsstämma
2019-02-28 - Bokslutskommuniké 2018
2018-12-18 - Extra Bolagsstämma 2018
2018-10-24 - Kvartalsrapport 2018-Q3
2018-08-29 - Kvartalsrapport 2018-Q2
2018-05-24 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2018-04-11 - Årsstämma
2018-03-22 - Bokslutskommuniké 2017
2017-08-29 - Kvartalsrapport 2017-Q2
2017-05-09 - Kvartalsrapport 2017-Q1
2017-04-26 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2017-04-25 - Årsstämma
2017-02-24 - Bokslutskommuniké 2016
2016-11-16 - Kvartalsrapport 2016-Q3
2016-10-19 - Extra Bolagsstämma 2016
2016-08-31 - Kvartalsrapport 2016-Q2
2016-04-20 - Kvartalsrapport 2016-Q1
2016-02-25 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2016-02-24 - Årsstämma
2016-02-04 - Bokslutskommuniké 2015
2015-11-13 - Kvartalsrapport 2015-Q3
2015-09-04 - Kvartalsrapport 2015-Q2
2015-07-22 - Extra Bolagsstämma 2015
2015-05-07 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2015-05-06 - Årsstämma
2015-04-17 - Kvartalsrapport 2015-Q1
2015-02-20 - Bokslutskommuniké 2014
2014-12-17 - Extra Bolagsstämma 2014
2014-11-28 - Kvartalsrapport 2014-Q3
2014-11-14 - Kvartalsrapport 2014-Q3
2014-08-29 - Kvartalsrapport 2014-Q2
2014-06-12 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2014-06-11 - Årsstämma
2014-05-16 - Kvartalsrapport 2014-Q1
2014-02-21 - Bokslutskommuniké 2013
2013-11-15 - Kvartalsrapport 2013-Q3
2013-08-28 - Kvartalsrapport 2013-Q2
2013-06-17 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2013-06-14 - Årsstämma
2013-05-17 - Kvartalsrapport 2013-Q1
2013-02-22 - Bokslutskommuniké 2012
2012-11-30 - Kvartalsrapport 2012-Q3
2012-07-31 - Kvartalsrapport 2012-Q2
2012-06-20 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2012-06-19 - Årsstämma
2012-04-20 - Kvartalsrapport 2012-Q1
2012-02-21 - Bokslutskommuniké 2011
2011-11-04 - Kvartalsrapport 2011-Q3
2011-08-12 - Kvartalsrapport 2011-Q2
2011-05-06 - Kvartalsrapport 2011-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
iZafe Group är ett Life Science-bolag inriktat på utveckling och marknadsföring av digitala medicinska lösningar för läkemedelshantering i hemmet. Bolaget erbjuder bland annat en läkemedelsrobot, SaaS-lösningar och en uppkopplad dosettask. Produkterna ämnar minska risken för felmedicinering. Kunderna utgörs av privatpersoner, läkemedelsbolag samt offentliga och privata vårdgivare globalt. iZafe Group har sitt huvudkontor i Stockholm.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-03-09 09:00:00

February has been a month where several important pieces have fallen into place for iZafe Group. We have been awarded a framework agreement in ADDA’s national procurement of medication dispensing robots and at the same time secured new growth capital to accelerate sales, installations and international expansion.

Over the past few years, we have built a solid foundation with more municipalities, new markets and a growing partner network. With ADDA now in place and a strengthened organization, we are entering the next phase where the focus is on scaling deliveries of Dosell and meeting the increasing demand.

Sweden – ADDA opens the door for broader adoption
The most significant event in February is the award in Sweden’s first national procurement of medication dispensing robots through ADDA. The framework agreement enables municipalities across the country to more easily procure Dosell via ADDA without having to conduct their own full procurement processes.

The standstill period runs until March 10, which means the agreement can be signed on March 11. We see this as an important milestone that creates new opportunities for broader adoption of Dosell in Swedish elderly care.

During the winter, many municipalities have been waiting for this decision before moving forward in their processes. February has therefore been relatively quiet in terms of new agreements, but we see the award decision as crucial for enabling several ongoing dialogues to move forward.

At the same time, some municipalities continue to conduct their own procurements outside ADDA. During February we have worked intensively with several such processes and hope to receive decisions in some of them during March.

Interest from municipalities remains strong. During February we conducted five additional product demonstrations and several tender presentations. We also continue to be contacted directly by municipalities interested in learning more about how Dosell can contribute to safer medication management.

An important milestone during the month is that a municipality previously working with another supplier has been running a pilot with Dosell since November. The outcome has been very positive and the municipality has now placed an order for an additional 40 units, thereby replacing its previous solution.

We have also initiated the onboarding of two new municipalities that will begin their implementations in March. At the same time, we see a clear trend where more municipalities are moving from pilot projects to broader deployment.

Growth capital to accelerate the next phase
During February, a directed share issue of approximately SEK 19.8 million was completed. The capital has been raised to further accelerate the company’s growth.

The new capital will be used, among other things, to strengthen the organization, increase the installation pace of Dosell and meet the growing demand from municipalities and partners. With more markets and an expanding pipeline, the focus is now on ensuring that we have the right resources in place to deliver in line with demand.

The Netherlands – continued scaling
Development in the Netherlands continues steadily and the market shows clear structural growth. During February we held several meetings with healthcare providers on how Dosell can be scaled up following initial implementations.

In the coming months, approximately 30 new departments within existing care providers are expected to begin using Dosell.

We have also completed several integrations, including with the system Bprocare, which simplifies implementation within existing healthcare workflows.

To further strengthen our presence, we have now recruited a Country Manager for the Netherlands. The role will focus on developing both direct sales and partner relationships, while creating a more scalable commercial structure to support continued growth in the market.

Norway – ready for rollout
In Norway, everything is now prepared for the rollout in the six municipalities included in the procurement we previously won together with our partner Vakt og Alarm.

Vakt og Alarm is a committed partner that sees strong potential in Dosell and in how the solution can contribute to more efficient medication management in Norwegian home care. Demand for medication dispensing solutions in Norway is high, and together we see strong opportunities to grow in this market. During February we also submitted a bid in another Norwegian procurement.

Finland, Iceland and Spain
Together with our partners, work also continues in our other markets. In Finland, Iceland and Spain, ongoing activities are underway to develop collaborations, strengthen market presence and create conditions for future implementations.

Although we do not have specific news to report from these markets this month, the work with our partners continues in a positive direction, with a focus on developing partnerships, strengthening market presence and preparing for future implementations.

Looking ahead – a strong position heading into spring
With the ADDA award, new growth capital to strengthen the organization and continued strong demand, we are entering the spring with good visibility.

During March, the focus will be on finalizing the ADDA process, receiving decisions in ongoing procurements, launching implementations with new municipalities in Sweden, continuing the scaling in the Netherlands and supporting our partners in other markets.

We will continue to work purposefully to make Dosell a natural part of the future of medication management.

Thank you for following our journey.